Skip to content

A randomised controlled trial examining the effects of root-securing blood-activating dredging-collateral Traditional Chinese Medicinal formula on proteinuria in diabetic kidney disease

A randomised controlled trial examining the effects of root-securing blood-activating dredging-collateral Traditional Chinese Medicinal formula on proteinuria in diabetic kidney disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-12001926
Enrollment
Unknown
Registered
2012-02-10
Start date
2012-02-20
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic kidney disease

Interventions

TCM group:root-securing blood-activating dredging-collateral Traditional Chinese Medicinal formula
Irbesartan goup:Irbesartan

Sponsors

Teaching Hospital of Chengdu University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. patients must meet the following two diagnostic criteria: (1) Symptoms of diabetes and a casual plasma glucose >= 11.1mmol/l or fasting plasma glucose >=7.0mmol/l or oral glucose tolerance test – two-hour plasma glucose >= 11.1mmol/l and (2) ACR >=300mg/g or 24h UAE >=300mg/24h and glomerular filtration rate (GFR)>=30ml/min.; 2. Diabetes is under control (fasting plasma glucose =30g/L; 6. patients who signed the consent forms.

Exclusion criteria

Exclusion criteria: 1. 24 urinary protein >=3.5g; 2. non-diabetes-induced kidney disease and kidney transplant; 3. intolerant to oral agents or suffered from severe malabsorption; 4. uncontrollable urinary infection and the infections which influence the measurements for urinary protein; 5. pregnancy or lactation; 6. allergic to Traditional Chinese Medicine or ARBs or allergic constitution; 7. severe primary heart, brain, liver and hematopoietic system comorbidities; mental disorders; 8. expected survival time < 1 year; 9. participated in other clinical trials within the past 30 days.

Design outcomes

Primary

MeasureTime frame
the rate of the change in ACR;

Secondary

MeasureTime frame
the level of ACR;24h urinary protein;eGFR;routine urinalysis;blood glucose;glycated hemoglobin;

Countries

China

Contacts

Public ContactMing Chen
chenming6699@yahoo.com.cn+86 18980880236

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026